Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CAMP4 Therapeutics Corporation (Nasdaq: CAMP) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered offerings. CAMP4 identifies itself in these filings as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics and antisense oligonucleotide (ASO) drug candidates to upregulate gene expression for genetic diseases.
Through its Form 8-K filings, CAMP4 reports material events such as securities purchase agreements, private placements, and underwritten offerings of common stock registered on Form S-3. These filings describe how the company expects to use proceeds to support preclinical and clinical development of product candidates, including its SYNGAP1 program, and to fund working capital and general corporate purposes.
CAMP4’s 8-K filings also detail strategic collaboration agreements, including a research, collaboration and license agreement with GSK covering antisense oligonucleotide therapeutics targeting regulatory RNAs for neurodegenerative and kidney disease indications. The filings outline key terms such as exclusive worldwide licenses under certain patents and know-how, upfront payments, potential development and commercial milestones, and tiered royalties on net sales.
Additional 8-Ks address corporate governance and compensation matters, including changes to the board of directors, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and registration rights agreements associated with private placements. As an emerging growth company, CAMP4 uses these reports to communicate significant operational, financing, and collaboration developments.
On Stock Titan, investors can review CAMP4’s filings alongside AI-powered summaries that explain the significance of each document. Users can quickly see highlights from annual and quarterly reports when available, track current reports on Form 8-K, and monitor equity financing terms, collaboration structures, and other regulatory disclosures relevant to CAMP4’s RNA-targeting therapeutic pipeline.
Camp4 Therapeutics Schedule 13D/A reports that Enavate Sciences GP, LLC and Everest Aggregator, LP each beneficially own 3,785,802 shares of Camp4 common stock, representing 8.1% of the class after a private placement. The amendment states the reported percentage is calculated using 20,161,073 shares outstanding as of August 5, 2025 plus 26,717,414 shares issued in a private placement that closed September 11, 2025. The filing clarifies that the change in reported percentage is due to dilution from the new issuance, not purchases or sales by the reporting persons, and discloses that James P. Boylan resigned from Camp4’s board effective September 9, 2025.
Camp4 Therapeutics Schedule 13D/A reports that Enavate Sciences GP, LLC and Everest Aggregator, LP each beneficially own 3,785,802 shares of Camp4 common stock, representing 8.1% of the class after a private placement. The amendment states the reported percentage is calculated using 20,161,073 shares outstanding as of August 5, 2025 plus 26,717,414 shares issued in a private placement that closed September 11, 2025. The filing clarifies that the change in reported percentage is due to dilution from the new issuance, not purchases or sales by the reporting persons, and discloses that James P. Boylan resigned from Camp4’s board effective September 9, 2025.
Camp4 Therapeutics Schedule 13D/A reports that Enavate Sciences GP, LLC and Everest Aggregator, LP each beneficially own 3,785,802 shares of Camp4 common stock, representing 8.1% of the class after a private placement. The amendment states the reported percentage is calculated using 20,161,073 shares outstanding as of August 5, 2025 plus 26,717,414 shares issued in a private placement that closed September 11, 2025. The filing clarifies that the change in reported percentage is due to dilution from the new issuance, not purchases or sales by the reporting persons, and discloses that James P. Boylan resigned from Camp4’s board effective September 9, 2025.
Camp4 Therapeutics Schedule 13D/A reports that Enavate Sciences GP, LLC and Everest Aggregator, LP each beneficially own 3,785,802 shares of Camp4 common stock, representing 8.1% of the class after a private placement. The amendment states the reported percentage is calculated using 20,161,073 shares outstanding as of August 5, 2025 plus 26,717,414 shares issued in a private placement that closed September 11, 2025. The filing clarifies that the change in reported percentage is due to dilution from the new issuance, not purchases or sales by the reporting persons, and discloses that James P. Boylan resigned from Camp4’s board effective September 9, 2025.
Camp4 Therapeutics amended a Schedule 13D to report participation by Polaris-related investors in a private placement and updated beneficial ownership figures. PP VII and PEF VII purchased 1,221,721 and 85,468 shares, respectively, at $1.53 per share on September 11, 2025, for aggregate amounts of $1,869,233.13 and $130,766.04.
The Purchase Agreement contemplates an Initial Closing issuing 26,681,053 shares and pre-funded warrants for 6,003,758 shares at $1.53 per share (pre-funded warrants at $1.5299). Management subscribed for additional small tranches at $1.65 per share, producing approximately $50.1 million of gross proceeds at the Initial Closing before fees. A Second Closing could issue up to 32,721,172 more shares/pre-funded warrants if a CTA milestone is met and either a $7.50 VWAP threshold is achieved or investors holding a majority waive the price condition. A Registration Rights Agreement obligates the issuer to register the resale of the issued shares and underlying warrant shares.
Camp4 Therapeutics amended a Schedule 13D to report participation by Polaris-related investors in a private placement and updated beneficial ownership figures. PP VII and PEF VII purchased 1,221,721 and 85,468 shares, respectively, at $1.53 per share on September 11, 2025, for aggregate amounts of $1,869,233.13 and $130,766.04.
The Purchase Agreement contemplates an Initial Closing issuing 26,681,053 shares and pre-funded warrants for 6,003,758 shares at $1.53 per share (pre-funded warrants at $1.5299). Management subscribed for additional small tranches at $1.65 per share, producing approximately $50.1 million of gross proceeds at the Initial Closing before fees. A Second Closing could issue up to 32,721,172 more shares/pre-funded warrants if a CTA milestone is met and either a $7.50 VWAP threshold is achieved or investors holding a majority waive the price condition. A Registration Rights Agreement obligates the issuer to register the resale of the issued shares and underlying warrant shares.
Camp4 Therapeutics amended a Schedule 13D to report participation by Polaris-related investors in a private placement and updated beneficial ownership figures. PP VII and PEF VII purchased 1,221,721 and 85,468 shares, respectively, at $1.53 per share on September 11, 2025, for aggregate amounts of $1,869,233.13 and $130,766.04.
The Purchase Agreement contemplates an Initial Closing issuing 26,681,053 shares and pre-funded warrants for 6,003,758 shares at $1.53 per share (pre-funded warrants at $1.5299). Management subscribed for additional small tranches at $1.65 per share, producing approximately $50.1 million of gross proceeds at the Initial Closing before fees. A Second Closing could issue up to 32,721,172 more shares/pre-funded warrants if a CTA milestone is met and either a $7.50 VWAP threshold is achieved or investors holding a majority waive the price condition. A Registration Rights Agreement obligates the issuer to register the resale of the issued shares and underlying warrant shares.
Camp4 Therapeutics amended a Schedule 13D to report participation by Polaris-related investors in a private placement and updated beneficial ownership figures. PP VII and PEF VII purchased 1,221,721 and 85,468 shares, respectively, at $1.53 per share on September 11, 2025, for aggregate amounts of $1,869,233.13 and $130,766.04.
The Purchase Agreement contemplates an Initial Closing issuing 26,681,053 shares and pre-funded warrants for 6,003,758 shares at $1.53 per share (pre-funded warrants at $1.5299). Management subscribed for additional small tranches at $1.65 per share, producing approximately $50.1 million of gross proceeds at the Initial Closing before fees. A Second Closing could issue up to 32,721,172 more shares/pre-funded warrants if a CTA milestone is met and either a $7.50 VWAP threshold is achieved or investors holding a majority waive the price condition. A Registration Rights Agreement obligates the issuer to register the resale of the issued shares and underlying warrant shares.
Polaris-related investors purchased shares of Camp4 Therapeutics in a private placement on September 11, 2025. Polaris Partners VII, L.P. and Polaris Entrepreneurs' Fund VII, L.P. acquired common stock at $1.53 per share under a Securities Purchase Agreement dated September 9, 2025. Reported purchases include 1,221,721 shares and 85,468 shares respectively. After the transactions, the filing shows beneficial holdings attributed indirectly to Polaris entities totaling 2,825,500 shares, 197,661 shares, and an additional 909,090 shares held by related Polaris funds or entities. Multiple Polaris-affiliated entities and named managing members disclaim beneficial ownership except for pecuniary interests.
Camp4 Therapeutics insider purchases reported by director and 10% owner Nashat Amir. On 09/11/2025 Polaris-affiliated entities purchased shares in a private placement at $1.53 per share under a Securities Purchase Agreement dated 09/09/2025. Purchases reported include 1,221,721 shares by Polaris Partners VII, L.P. and 85,468 shares by Polaris Entrepreneurs' Fund VII, L.P., with combined reported beneficial ownership following the transactions shown as 2,825,500 and 197,661 shares respectively and an additional 909,090 shares held indirectly by Polaris Partners X, L.P.
The filing discloses indirect ownership through management entities and contains standard disclaimers that the managing entities and reported persons disclaim beneficial ownership except to the extent of pecuniary interests.
Camp4 Therapeutics officer purchased 6,060 shares in a private placement at $1.65 per share. Yuri Maricich, identified as Chief Medical Officer and a reporting person, acquired the shares pursuant to a Securities Purchase Agreement dated September 9, 2025, with the transaction dated September 11, 2025.
The purchase was part of a private placement involving institutional investors and certain directors, employees, and consultants. Following the purchase, the reporting person directly owns 6,060 shares.
CAMP4 Therapeutics announced a private investment (September 2025 Private Placement) in which institutional PIPE investors, including 5AM-affiliated funds, purchased shares and pre-funded warrants in an initial closing. Ventures VII bought 2,941,176 shares at $1.53 per share for $4.5 million on September 11, 2025. The Initial Closing issued 26,681,053 shares and pre-funded warrants to PIPE investors.
The PIPE includes an option for a Second Closing to sell up to 32,721,172 additional shares or pre-funded warrants if two triggers occur: (i) regulatory acceptance to commence a clinical trial for the company’s SYNGAP1-related disorder candidate and (ii) either a VWAP-based price threshold of $7.50 during a designated Measurement Period or a waiver by PIPE investors. The investors received registration rights; the issuer must file an initial registration statement within 60 days of the Initial Closing and use best efforts to keep it effective for resale.
Reporting persons disclose direct holdings by 5AM vehicles totaling specific stakes (e.g., Ventures VI: 2,625,145 shares; Ventures VII: 2,941,176 shares; Opportunities II: 302,770 shares), and aggregate beneficial ownership attributed to individuals Schwab and Parmar of 5,869,091 shares (12.5%) based on the stated share base.
CAMP4 Therapeutics announced a private investment (September 2025 Private Placement) in which institutional PIPE investors, including 5AM-affiliated funds, purchased shares and pre-funded warrants in an initial closing. Ventures VII bought 2,941,176 shares at $1.53 per share for $4.5 million on September 11, 2025. The Initial Closing issued 26,681,053 shares and pre-funded warrants to PIPE investors.
The PIPE includes an option for a Second Closing to sell up to 32,721,172 additional shares or pre-funded warrants if two triggers occur: (i) regulatory acceptance to commence a clinical trial for the company’s SYNGAP1-related disorder candidate and (ii) either a VWAP-based price threshold of $7.50 during a designated Measurement Period or a waiver by PIPE investors. The investors received registration rights; the issuer must file an initial registration statement within 60 days of the Initial Closing and use best efforts to keep it effective for resale.
Reporting persons disclose direct holdings by 5AM vehicles totaling specific stakes (e.g., Ventures VI: 2,625,145 shares; Ventures VII: 2,941,176 shares; Opportunities II: 302,770 shares), and aggregate beneficial ownership attributed to individuals Schwab and Parmar of 5,869,091 shares (12.5%) based on the stated share base.
CAMP4 Therapeutics announced a private investment (September 2025 Private Placement) in which institutional PIPE investors, including 5AM-affiliated funds, purchased shares and pre-funded warrants in an initial closing. Ventures VII bought 2,941,176 shares at $1.53 per share for $4.5 million on September 11, 2025. The Initial Closing issued 26,681,053 shares and pre-funded warrants to PIPE investors.
The PIPE includes an option for a Second Closing to sell up to 32,721,172 additional shares or pre-funded warrants if two triggers occur: (i) regulatory acceptance to commence a clinical trial for the company’s SYNGAP1-related disorder candidate and (ii) either a VWAP-based price threshold of $7.50 during a designated Measurement Period or a waiver by PIPE investors. The investors received registration rights; the issuer must file an initial registration statement within 60 days of the Initial Closing and use best efforts to keep it effective for resale.
Reporting persons disclose direct holdings by 5AM vehicles totaling specific stakes (e.g., Ventures VI: 2,625,145 shares; Ventures VII: 2,941,176 shares; Opportunities II: 302,770 shares), and aggregate beneficial ownership attributed to individuals Schwab and Parmar of 5,869,091 shares (12.5%) based on the stated share base.
CAMP4 Therapeutics announced a private investment (September 2025 Private Placement) in which institutional PIPE investors, including 5AM-affiliated funds, purchased shares and pre-funded warrants in an initial closing. Ventures VII bought 2,941,176 shares at $1.53 per share for $4.5 million on September 11, 2025. The Initial Closing issued 26,681,053 shares and pre-funded warrants to PIPE investors.
The PIPE includes an option for a Second Closing to sell up to 32,721,172 additional shares or pre-funded warrants if two triggers occur: (i) regulatory acceptance to commence a clinical trial for the company’s SYNGAP1-related disorder candidate and (ii) either a VWAP-based price threshold of $7.50 during a designated Measurement Period or a waiver by PIPE investors. The investors received registration rights; the issuer must file an initial registration statement within 60 days of the Initial Closing and use best efforts to keep it effective for resale.
Reporting persons disclose direct holdings by 5AM vehicles totaling specific stakes (e.g., Ventures VI: 2,625,145 shares; Ventures VII: 2,941,176 shares; Opportunities II: 302,770 shares), and aggregate beneficial ownership attributed to individuals Schwab and Parmar of 5,869,091 shares (12.5%) based on the stated share base.
Camp4 Therapeutics insider Kelly Gold, who serves as Chief Financial Officer, purchased 6,060 shares of Camp4 common stock at $1.65 per share in a private placement dated September 11, 2025. After the transaction, the reporting person beneficially owned 67,877 shares. The purchase was made pursuant to a Securities Purchase Agreement executed by the company, certain institutional investors, and participating directors, employees, and consultants.
This disclosure is a routine Section 16 filing showing an officer buy in a private placement rather than an open-market trade. It documents insider participation alongside institutional investors but does not provide additional financial, valuation, or company-operational context in this filing.
Camp4 Therapeutics CEO and director Josh Mandel-Brehm reported acquiring 6,060 shares of the company's common stock on 09/11/2025 at a purchase price of $1.65 per share. The acquisition was made in a private placement governed by a Securities Purchase Agreement dated 09/09/2025 involving certain institutional investors and company insiders. Following the transaction, the reporting person beneficially owned 278,417 shares. The filing is a Form 4 disclosure of changes in beneficial ownership and does not include derivative transactions.
Camp4 Therapeutics director Richard A. Young acquired 15,151 shares of Camp4 Therapeutics Corp (CAMP) in a private placement on 09/11/2025 at $1.65 per share under a Securities Purchase Agreement dated 09/09/2025. After this purchase the reporting person beneficially owned 170,010 shares. The Form 4 was filed individually and executed by an attorney-in-fact. The filing states the purchase involved institutional investors and certain directors, employees and consultants; no derivative transactions or other securities changes are reported.
CAMP Therapeutics reported a private placement and related registration rights, board resignations, and management changes. The company entered into a Purchase Agreement providing for sales of securities in one or two closings and agreed to file an initial registration statement within 60 days of the Initial Closing (and, if applicable, a Second Registration Statement within 30 days of a Second Closing) to permit resale of the issued shares and warrant shares. The company committed to use reasonable best efforts to have registration statements become effective within prescribed SEC timelines and to keep them effective under Rule 415 until resale conditions are met. Cash penalties apply for registration failures and customary reciprocal indemnities were granted. Separately, three directors resigned effective September 9, 2025, Douglas Williams, PhD was named Chair, and Daniel Tardiff, PhD was elevated to Chief Scientific Officer effective October 1, 2025. The securities were issued in a private placement relying on Section 4(a)(2).